Jason A. Sprowl PhD
Jason A. Sprowl
PhD
Assistant Professor
Department of Pharmaceutical Sciences
Specialty/Research Focus
Cancer Chemotherapy; Drug Delivery; Drug Targeting; Drug Transport; Drug Utilization Research; Drug-Drug Interactions; Pharmacodynamic; Pharmacogenetics; Pharmacogenomics; Pharmacogenomics; Pharmacokinetic; Pharmacokinetics; PK/PD; Toxicology; Translational Research
Professional Summary:
Our research program primarily conducts translational studies that aim to identify and characterize regulators of drug disposition which contributes to the variability of drug toxicity or efficacy in cancer patients. We currently focus on the role of transporter proteins in regulating drug or nutrient uptake and accumulation.
Education and Training:
- Postdoctoral Fellow, Pharmaceutical Sciences, St. Jude Children‘s Research hospital (2014)
- PhD, Biomolecular Sciences, Laurentian University (2010)
- BS, Biochemistry, Laurentian University (2004)
Employment:
- Assistant Professor, Pharmaceutical Sciences, University at Buffalo (2018-present)
- Assistant Professor, Pharmaceutical, Social and Administrative Sciences, D'Youville College (2014–2018)
Awards and Honors:
- CTSI KL2 Scholar (2020)
- AACP New Investigator Award (2019)
- Faculty Member of the Year - D‘Youville College, School of Pharmacy, Department of Pharmaceutical, Social and Administrative Sciences (2018)
- Carl Jackson Postdoctoral Excellence Award (2014)
- David Goldstein Trainee Award (2012)
Research Expertise:
- Membrane Transporters: Role of transporters in regulating pharmacokinetics and pharmacodynamics of therapeutics. Membrane transporters as regulators of drug toxicity.
- Pharmacogenomics: Identification and characterization of proteins with genetic variation that can impact treatment outcome
Grants and Sponsored Research:
- July 2020–June 2022
Regulation of Cisplatin-induced Ototoxicity by the Monocarboxylate Transporter MCT6
Buffalo Translational Consortium
Role: Principal Investigator
$489,208 - May 2020–May 2022
Sustained Release of Luzindole
Buffalo Blue Sky Program
Role: Co-Investigator
$10,000 - June 2020–January 2022
SGLT Activity as a Mediator of Tyrosine Kinase Inhibitor Treatment Outcome
School of Pharmacy and Pharmaceutical Sciences Seed Support Program
Role: Principal Investigator
$7,500 - January 2019–January 2020
Regulation of SGLT1 Function by Tyrosine Kinase Inhibitors
AACP
Role: Principal Investigator
$9,864 - October 2018–January 2020
Kinase-mediated regulation of OATP Transporters
School of Pharmacy and Pharmaceutical Sciences Seed Support Program
Role: Principal Investigator
$5,000
Patents:
- TNF gene expression to assess response to taxanes or anthracyclines TNF-related gene expression used as a biomarker to measure response to taxanes or anthracycles (2014)
Journal Articles:
- Hayden ER, Chen M, Pasquariello KZ, Gibson AA, Petti JJ, Shen S, Qu J, Ong SS, Chen T, Jin Y, Uddin ME, Huang KM, Paz A, Sparreboom A, Hu S, Sprowl JA. Regulation of OATP1B1 Function by Tyrosine Kinase-mediated Phosphorylation. Clin Cancer Res. 2021; 27(15).
- Pasquariello KZ, Dey JM, Sprowl JA. Current Understanding of Membrane Transporters as Regulators or Targets for Cisplatin-Induced Hearing Loss. Mol Pharmacol. 2021.
- Huang KM, Leblanc AF, Uddin ME, Kim JY, Chen M, Eisenmann ED, Gibson AA, Li Y, Hong KW, DiGiacomo D, Xia SH, Alberti P, Chiorazzi A, Housley SN, Cope TC, Sprowl JA, Wang J, Loprinzi CL, Noonan A, Lustberg MB, Cavaletti G, Pabla N, Hu S, Sparreboom A. Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice. J Clin Invest. 2020; 130(9).
- Hu S, Sprowl JA. Strategies to Reduce Solute Carrier-mediated Toxicity. Clin Pharmacol Ther. 2018.
- Evers R, Piquette-Miller M, Polli JW, Russel FGM, Sprowl JA, Tohyama K, Ware JA, de Wildt SN, Xie W, Brouwer KLR. Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium. Clin Pharmacol Ther. 2018.
- Leblanc AF, Sprowl JA, Alberti P, Chiorazzi A, Arnold WD, Gibson AA, Hong KW, Pioso MS, Chen M, Huang KM, Chodisetty V, Costa O, Florea T, de Bruijn P, Mathijssen RH, Reinbolt RE, Lustberg MB, Sucheston-Campbell LE, Cavaletti G, Sparreboom A, Hu S. OATP1B2 deficiency protects against paclitaxel-induced neurotoxicity. J Clin Invest. 2018; 128(2).
- Hu S, Leblanc AF, Gibson AA, Hong KW, Kim JY, Janke LJ, Li L, Vasilyeva A, Finkelstein DB, Sprowl JA, Sweet DH, Schlatter E, Ciarimboli G, Schellens J, Baker SD, Pabla N, Sparreboom A. Identification of OAT1/OAT3 as Contributors to Cisplatin Toxicity. Clin Transl Sci. 2017; 10(5).
- Sprowl JA, Ong SS, Gibson AA, Hu S, Du G, Lin W, Li L, Bharill S, Ness RA, Stecula A, Offer SM, Diasio RB, Nies AT, Schwab M, Cavaletti G, Schlatter E, Ciarimboli G, Schellens JH, Isacoff EY, Sali A, Chen T, Baker SD, Sparreboom A, Pabla N. A phosphotyrosine switch regulates organic cation transporters. Nat Commun. 2016; 7.
- Pabla N, Gibson AA, Buege M, Ong SS, Li L, Hu S, Du G, Sprowl JA, Vasilyeva A, Janke LJ, Schlatter E, Chen T, Ciarimboli G, Sparreboom A. Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions. Proc Natl Acad Sci U S A. 2015; 112(16).
- Lanvers-Kaminsky C, Sprowl JA, Malath I, Deuster D, Eveslage M, Schlatter E, Mathijssen RH, Boos J, Jürgens H, Am Zehnhoff-Dinnesen AG, Sparreboom A, Ciarimboli G. Human OCT2 variant c.808G>T confers protection effect against cisplatin-induced ototoxicity. Pharmacogenomics. 2015; 16(4).
- Sprowl JA, Lancaster CS, Pabla N, Hermann E, Kosloske AM, Gibson AA, Li L, Zeeh D, Schlatter E, Janke LJ, Ciarimboli G, Sparreboom A. Cisplatin-induced renal injury is independently mediated by OCT2 and p53. Clin Cancer Res. 2014; 20(15).
- Sprowl JA, Sparreboom A. Uptake carriers and oncology drug safety. Drug Metab Dispos. 2014; 42(4).
- Sprowl JA, van Doorn L, Hu S, van Gerven L, de Bruijn P, Li L, Gibson AA, Mathijssen RH, Sparreboom A. Conjunctive therapy of cisplatin with the OCT2 inhibitor cimetidine: influence on antitumor efficacy and systemic clearance. Clin Pharmacol Ther. 2013; 94(5).
- Lancaster CS, Sprowl JA, Walker AL, Hu S, Gibson AA, Sparreboom A. Modulation of OATP1B-type transporter function alters cellular uptake and disposition of platinum chemotherapeutics. Mol Cancer Ther. 2013; 12(8).
- Sprowl JA, Ciarimboli G, Lancaster CS, Giovinazzo H, Gibson AA, Du G, Janke LJ, Cavaletti G, Shields AF, Sparreboom A. Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2. Proc Natl Acad Sci U S A. 2013; 110(27).
- de Graan AJ, Elens L, Sprowl JA, Sparreboom A, Friberg LE, van der Holt B, de Raaf PJ, de Bruijn P, Engels FK, Eskens FA, Wiemer EA, Verweij J, Mathijssen RH, van Schaik RH. CYP3A4*22 genotype and systemic exposure affect paclitaxel-induced neurotoxicity. Clin Cancer Res. 2013; 19(12).
- Sprowl JA, Ness RA, Sparreboom A. Polymorphic transporters and platinum pharmacodynamics. Drug Metab Pharmacokinet. 2012; 28(1).
- Heibein AD, Guo B, Sprowl JA, Maclean DA, Parissenti AM. Role of aldo-keto reductases and other doxorubicin pharmacokinetic genes in doxorubicin resistance, DNA binding, and subcellular localization. BMC Cancer. 2012; 12.
- Sprowl JA, Gregorc V, Lazzari C, Mathijssen RH, Loos WJ, Sparreboom A. Associations between ABCC2 polymorphisms and cisplatin disposition and efficacy. Clin Pharmacol Ther. 2012; 91(6).
- Ciarimboli G, Lancaster CS, Schlatter E, Franke RM, Sprowl JA, Pavenstädt H, Massmann V, Guckel D, Mathijssen RH, Yang W, Pui CH, Relling MV, Herrmann E, Sparreboom A. Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients. Clin Cancer Res. 2012; 18(4).
- Sprowl JA, Mikkelsen TS, Giovinazzo H, Sparreboom A. Contribution of tumoral and host solute carriers to clinical drug response. Drug Resist Updat. 2012; 15(1-2).
- Sprowl JA, Reed K, Armstrong SR, Lanner C, Guo B, Kalatskaya I, Stein L, Hembruff SL, Tam A, Parissenti AM. Alterations in tumor necrosis factor signaling pathways are associated with cytotoxicity and resistance to taxanes: a study in isogenic resistant tumor cells. Breast Cancer Res. 2012; 14(1).
- Reed K, Hembruff SL, Sprowl JA, Parissenti AM. The temporal relationship between ABCB1 promoter hypomethylation, ABCB1 expression and acquisition of drug resistance. Pharmacogenomics J. 2010; 10(6).
- Sprowl JA, Villeneuve DJ, Guo B, Young AJ, Hembruff SL, Parissenti AM. Changes in expression of cell wall turnover genes accompany inhibition of chromosome segregation by bovine protein kinase C alpha expression in Saccharomyces cerevisiae. Cell Biol Int. 2007; 31(10).
Professional Memberships:
- American Society for Pharmacology and Experimental Therapeutics (ASPET) (2018–present)
- Rho Chi Society (2018–present)
- American Association of Colleges of Pharmacy (AACP) (2014–present)
- American Society For Clinical Pharmacology and Therapeutics (ASCPT) (2011–2015)
- American Association For Cancer Research (AACR) (2008–2015)
Presentations:
- "Influence of tyrosine kinase inhibitors and tyrosine phosphorylation sites on SGLT1 function" American Society for Clinical Pharmacology and Therapeutics Annual Meeting, American Society for Clinical Pharmacology and Therapeutics (2021)
- "Regulation of OATP1B1 activity by tyrosine kinase-mediated phosphorylation" American Society for Clinical Pharmacology and Therapeutics Annual Meeting, American Society for Clinical Pharmacology and Therapeutics (2021)
- "Managing Drug Efficacy and Safety when Transporters get Perturbed" American Society for Clinical Pharmacology and Therapeutics Annual Meeting, American Society for Clinical Pharmacology and Therapeutics (2021)
- "Influence of kinase inhibitors on membrane transporters – risk of drug-drug interactions and adverse events" Roswell Park Comprehensive Cancer Center Lung Translational Research Group Meeting, Roswell Park Comprehensive Cancer Center Lung Translational Research Group (2021)
- "Membrane Transporter Community Network and Community Experience" American Society for Clinical Pharmacology and Therapeutics Annual Meeting, American Society for Clinical Pharmacology and Therapeutics (2021)
- "Proteomics-informed prediction of transporter-enzyme interplay in drug disposition" ASCPT Webinar, American Society for Clinical Pharmacology and Therapeutics (2021)
- "Genomics and Toxicology – Genetic Predisposition to Drug Toxicity”" North American Congress of Clinical Toxicology Annual Meeting, North American Congress of Clinical Toxicology (2020)
- "Regulation of SGLT1 Function by Tyrosine Kinase Inhibitors" AACP Annual Meeting, AACP (2020)
- "Role of transporters and S100A8/A9 in paclitaxel-induced peripheral neuropathy" Experimental Biology, ASPET (2020)
- "Phosphorylation and function of OATP1B1 with tyrosine kinase inhibitors" Experimental Biology, ASPET (2020)
- "Therapeutic Impact and Detection of Membrane Transporter Polymorphisms" ASCPT Webinar, American Society for Clinical Pharmacology and Therapeutics (2020)
- "Tyrosine Kinase Mediated Regulation of OATP1B1" 4th Annual Division of Pharmaceutics Scientific Retreat, The Ohio State University (2019)
- "Characterization of OATP1B1 and OATP1B3 inhibition by Nilotinib" Experimental Biology, ASPET (2019)
- "Genetic and Pharmacological Inhibition of OCT2 protects rats against oxaliplatin-induced peripheral neuropathy" Experimental Biology 2019, ASPET (2019)
- "Changes in Expression and Activity of Transporters: Do They Impact Pharmacokinetics and Toxicity of Drugs" ASCPT Webinar, American Society for Clinical Pharmacology and Therapeutics (2018)
- "Targeting transporters to ameliorate chemotherapy-induced peripheral neuropathy" EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, EORTC-NCI-AACR (2018)
- "Genetic and pharmacological inhibition of OCT2 protects Rattus Norvegicus from Oxaliplatin-induced peripheral neuropathy" 3rd Annual Division of Pharmaceutics Scientific Retreat, The Ohio State University (2018)
- "Targeting OATP1B2 to ameliorate paclitaxel-induced chronic peripheral neuropathy" American Society for Clinical Pharmacology and Therapeutics Annual Meeting, American Society for Clinical Pharmacology and Therapeutics (2018)
- "Influence of Nilotinib and different Tyrosine Kinases on OATP1B1 Function" 2nd Annual Division of Pharmaceutics Scientific Retreat, The Ohio State University, Pharmaceutical Sciences (2017)
- "OATP1B2-deficiency protects against paclitaxel-induced neuropathy" American Society for Clinical Pharmacology and Therapeutics Annual Meeting, American Society for Clinical Pharmacology and Therapeutics (2016)
- "Identification of OAT1/OAT3 as contributors to cisplatin nephrotoxicity" American Association for Cancer Research Annual Meeting, American Association for Cancer Research (2015)
- "Tyrosine phosphorylation is essential for OCT2 function and a target of inhibition by TKIs" American Association for Cancer Research Annual Meeting, American Association for Cancer Research (2015)
- "Organic cation transporters mediate cisplatin and oxaliplatin side effects" International Conference of Anticancer Research, Anticancer Research (2014)
- "Amelioration of oxaliplatin neurotoxicity by dasatinib" American Society for Clinical Pharmacology and Therapeutics Annual Meeting, American Society for Clinical Pharmacology and Therapeutics (2013)
- "Conjunctive therapy of cisplatin with OCT inhibitors: influence on antitumor efficacy and systemic clearance" American Society for Clinical Pharmacology and Therapeutics Annual Meeting, American Society for Clinical Pharmacology and Therapeutics (2013)
- "Identification of tyrosine kinase inhibitors as modulators of OCT2 function" EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, EORTC-NCI-AACR (2012)
- "Association of ABCC2 polymorphisms with cisplatin disposition and efficacy" American Society for Clinical Pharmacology and Therapeutics Annual Meeting, American Society for Clinical Pharmacology and Therapeutics (2012)
- "Contribution of p53 signaling to cisplatin nephrotoxicity in Oct1/Oct2-deficient mice" American Society for Clinical Pharmacology and Therapeutics Annual Meeting, American Society for Clinical Pharmacology and Therapeutics (2012)
- "Oxaliplatin-induced peripheral neurotoxicity is dependent on OCT2-mediated transport" American Society for Clinical Pharmacology and Therapeutics Annual Meeting, American Society for Clinical Pharmacology and Therapeutics (2012)
- "Role of the 1C aldo-keto reductases in resistance to doxorubicin in MCF-7 breast cancer cells" American Association for Cancer Research Annual Meeting, American Association for Cancer Research (2010)
- "Resistance to TNFα in MCF-7 Cells during the acquisition of taxane resistance" American Association for Cancer Research Annual Meeting, American Association for Cancer Research (2009)
- "Clustering of anthracycline-containing lysosomes in drug-resistant MCF-7 cells in response to tesmilifene" American Association for Cancer Research Annual Meeting, American Association for Cancer Research (2008)
- "Role of promoter methylation in the induction of ABCB1 gene expression in anthracycline-resistant and paclitaxel-resistant breast tumor cells" American Association for Cancer Research Annual Meeting, American Association for Cancer Research (2008)
Service Activities:
- ASCPT Membrane Transporter Community; Chair (2021–present)
- Curricular Fall Planning Sub-Committee; Member (2020)
- ASCPT Membrane Transporter Community; Vice-Chair (2020–2021)
- ASCPT Pharmacogenomic Community; Member (2019–2020)
- Outcomes and Assessment Committee; Vice-Chair (2019–present)
- Outcomes and Assessment Committee; Member (2018–2019)